TRIANGLE PHARMACEUTICALS INC Form 15-12G January 24, 2003

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 000-21589

Triangle Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

4 University Place 4611 University Drive Durham, North Carolina 27707 (919) 493-5980

(Address, including zip code, and telephone number, including area code, of registrant s principal executive offices)

Common Stock par value \$0.001 per share

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

| Rule 12g-4(a)(1)(i) | ý | Rule $12h-3(b)(1)(i)$ | ý |
|----------------------|---|-----------------------|---|
| Rule 12g-4(a)(1)(ii) | О | Rule 12h-3(b)(1)(ii) | o |
| Rule 12g-4(a)(2)(i) | О | Rule 12h-3(b)(2)(i) | o |
| Rule 12g-4(a)(2)(ii) | О | Rule 12h-3(b)(2)(ii) | o |
| | | Rule 15d-6 | o |

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 15-12G

| Approximate number of holders of record as of the certification or notice date: One | | | | | | |
|---|---|-----|---|--|--|--|
| | ant to the requirements of the Securities Exc on its behalf by the undersigned duly author | | ngle Pharmaceuticals, Inc. has caused this certification/notice to be | | | |
| Date: | January 24, 2003 | By: | /s/ GREGG ALTON Gregg Alton Secretary | | | |